ShRNA for targeted silence of ABHD2 gene expression, lentiviral expression vector and application of shRNA and lentiviral expression vector

By targeting shRNA and lentiviral expression vectors of the ABHD2 gene, it inhibits the proliferation of ovarian cancer cells and promotes apoptosis, solving the problems of early diagnosis and treatment of ovarian cancer, improving the cure rate and reducing toxic side effects.

CN118910045APending Publication Date: 2024-11-08NANTONG UNIV
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202410950640.2
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-07-16
Publication Date
2024-11-08

AI Technical Summary

Technical Problem

The prior art has failed to effectively solve the early diagnosis and treatment of ovarian cancer, especially ovarian granule cell carcinoma. The traditional treatment methods have great toxic side effects and low cure rates, and there is a lack of targeted treatment plans for the ABHD2 gene.

Method used

A shRNA and lentiviral expression vector targeting the silencing of the ABHD2 gene were designed, and a recombinant lentiviral expression vector was constructed to knock down the ABHD2 gene, inhibit the proliferation of ovarian cancer cells and promote apoptosis.

Benefits of technology

By targeting silencing the expression of ABHD2 gene, it significantly inhibits the proliferation vitality of ovarian cancer cells and increases the proportion of apoptosis, providing a new therapeutic strategy for ovarian cancer, improving the cure rate and reducing the toxic side effects of treatment.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN118910045A_ABST
    Figure CN118910045A_ABST
Patent Text Reader

Abstract

The invention discloses shRNA (short hairpin ribonucleic acid) for targeted silencing of ABHD2 gene expression, a lentiviral expression vector and application of the shRNA. Nucleotide sequences of the shRNA are shown as SEQ ID NO. 1 and SEQ ID NO. 2. A KGN cell line for knocking down ABHD2 is established by constructing a recombinant lentiviral expression vector of ABHD2-shRNA, a CCK8 experiment and a Hoech33342 staining experiment prove that the proliferation activity of ovarian cancer cells can be inhibited and the apoptosis of the cancer cells can be increased by silencing the expression of the ABHD2 gene, and a new strategy is provided for the treatment of the ovarian cancer. The invention has wide application range, is not only suitable for laboratory research, but also hopefully provides an effective tool for clinical treatment of ovarian cancer, improves the cure rate of ovarian cancer and improves the life quality of patients, and has wide application prospect and important practical significance in the field of ovarian cancer treatment.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention belongs to the field of biomedicine technology, and specifically relates to a shRNA for targeting and silencing ABHD2 gene expression, a lentiviral expression vector and applications thereof. Background Art

[0002] The ABHD2 (abhydrolase domain containing 2, acylglycerol lipase) gene is widely expressed in various organs of the human body. It encodes an acylglycerol lipase, which is an androgen-induced cell membrane-anchored protein that can catalyze the hydrolysis of endogenous cannabinoid arachidonoylglycerol from the cell membrane and participate in various physiological functions in the body. Studies have reported that ABHD2 is involved in the occurrence and development of various tumors. For example, ABHD2 has high expression characteristics in prostate cancer, hepatocellular carcinoma, and breast cancer, which promotes the spread, proliferation, and migration of cancer cells. It is a potential diagnostic method and a potential drug treatment target.

[0003] Ovarian cancer is a malignant tumor of the ovarian tumor. Its incidence rate ranks third among gynecological malignancies, but its mortality rate ranks first among gynecological cancers. It is the biggest disease that seriously threatens women's health. Ovarian cancer lacks symptoms in the early stage and screening is limited. Therefore, most patients are in the late stage when they seek medical treatment. In late stage cases, the efficacy is poor and traditional treatment has great toxic side effects. Even after cure, it is easy to relapse. Ovarian cancer can be divided into multiple subtypes according to its histological type, including serous ovarian cancer and granulosa cell carcinoma. Therefore, developing new targeted treatment options to increase the cure rate of ovarian cancer and reduce toxic side effects is the focus of treatment. Some studies have reported that in clinical serous ovarian cancer patients, the expression of ABHD2 is closely related to their malignancy and prognosis. However, there are no reports that clearly show the correlation between ABHD2 and ovarian granulosa cell carcinoma. Therefore, clarifying the association between ABHD2 and ovarian granulosa cell carcinoma is expected to provide new ideas for increasing the cure rate of ovarian cancer patients. In addition, since ABHD2 is also expressed in other types of cancer and is correlated, research on ABHD2 is also expected to be applied to the treatment of other cancers. Summary of the invention

[0004] In view of the deficiencies in the prior art, the present invention provides a shRNA, a lentiviral expression vector and applications thereof for targeted silencing of ABHD2 gene expression, which provides a specific treatment strategy for improving the cure rate of ovarian cancer by targeted inhibition of ABHD2, thereby improving the clinical outcomes of patients.

[0005] The present invention is achieved through the following technical solutions:

[0006] A shRNA targeting silencing ABHD2 gene expression, the nucleotide sequence of which is shown in SEQ ID NO.1 and SEQ ID NO.2.

[0007] A lentiviral expression vector containing the above-mentioned shRNA targeting silencing ABHD2 gene expression.

[0008] Use of the above-mentioned shRNA targeting silencing ABHD2 gene expression, or the above-mentioned lentiviral expression vector in the preparation of a drug for treating ovarian cancer.

[0009] Preferably, the treatment includes inhibiting the proliferation of ovarian cancer cells and increasing the apoptosis of ovarian cancer cells.

[0010] Preferably, the ovarian cancer cells are KGN cells.

[0011] A pharmaceutical composition for treating ovarian cancer, comprising the above-mentioned shRNA targeting silencing ABHD2 gene expression, or the above-mentioned lentiviral expression vector.

[0012] The beneficial effects of the present invention are as follows:

[0013] The present invention establishes a KGN cell line that knocks down ABHD2 by constructing a recombinant lentiviral expression vector of ABHD2-shRNA. CCK8 experiments and Hoechest33342 staining experiments prove that silencing the expression of the ABHD2 gene can inhibit the proliferation activity of ovarian cancer cells and increase the apoptosis of cancer cells, providing a new strategy for the treatment of ovarian cancer. The present invention uses the KGN cell line as the research object, and by silencing the expression of the ABHD2 gene, it reveals the important role of the gene in the growth of ovarian cancer cells, providing strong support for in-depth research on the pathogenesis of ovarian cancer and finding new therapeutic targets. The present invention has a wide range of applications, not only suitable for laboratory research, but also expected to provide an effective tool for the clinical treatment of ovarian cancer, improve the cure rate of ovarian cancer, and improve the quality of life of patients. It has broad application prospects and important practical significance in the field of ovarian cancer treatment. BRIEF DESCRIPTION OF THE DRAWINGS

[0014] Figure 1 This is a statistical diagram of the knockdown effect of the ABHD2 gene after KGN cells were transfected with the lentiviral expression vector pLKO.1-TRC-shABHD2 in Example 3;

[0015] Figure 2 This is a statistical diagram of cell proliferation after knocking down the ABHD2 gene in KGN cells in Example 4;

[0016] Figure 3 This is the fluorescence microscopy image of cell apoptosis after knocking down the ABHD2 gene in KGN cells in Example 5 (A) and the corresponding statistical graph (B). DETAILED DESCRIPTION

[0017] The present invention is further described in detail below with reference to the accompanying drawings and specific embodiments.

[0018] Unless otherwise specified, the technical means used in the following examples are all conventional means well known to those skilled in the art, and the experimental methods without specifying the specific conditions are all conventional methods in the art.

[0019] Unless otherwise specified, the materials and reagents used in the following examples can be obtained from commercial sources.

[0020] Example 1 Design of shRNA sequence for ABHD2 gene

[0021] The mRNA sequence of ABHD2 gene was obtained from the GenBank database (http: / / www.ncbi.nlm.nih.gov / genbank). Based on the principle of base complementarity, a pair of shRNA oligonucleotide chains were designed using primer software, and sequence comparison was performed on the NCBI website to verify its specificity.

[0022] The positive strand shABHD2-F and the antisense strand shABHD2-R of the shRNA are as follows:

[0023] shABHD2-F (SEQ ID NO. 1): 5'-CCGGTACGTGATCGTCCGGTGTTTGCTCGAGCAAACACCGGACGATCACGTATTTTTG-3';

[0024] shABHD2-R (SEQ ID NO. 2): 5'-AATTCAAAAATACGTGATCGTCCGGTGTTTGCTCGAGCAAACACCGGACGATCACGTA-3'.

[0025] The shRNA sequences designed above were synthesized by Genewir Biotech.

[0026] Example 2 Construction of ABHD2-shRNA Lentivirus Expression Vector

[0027] Take the sense chain shABHD2-F and antisense chain shABHD2-R designed in Example 1, add 2 μL sense chain (100 μM), 2 μL antisense chain (100 μM), 2 μL 10×Cutsmart buffer (Saiye Company), add ddH2O, and prepare a 20 μL reaction system. The forward and reverse interference sequences are annealed to form double-stranded sticky end DNA, and incubated at 98-100 ° C. After 4 minutes, it is slowly cooled at room temperature to reach room temperature. Connect to the double-enzyme-cut lentiviral knockdown plasmid vector pLKO.1-TRC. The ligation product was transformed into DH5α Escherichia coli competent cells by heat shock method, placed on LB solid medium containing ampicillin resistance and cultured at 37 ° C for 16 hours, and a single colony was picked and shaken in LB liquid medium containing ampicillin resistance, 37 ° C, 220 rpm, 16 hours, and the bacterial cells were collected to extract plasmids, enzyme-cutting verification plasmids, and sent to the company for sequencing verification. Sequencing shows that the successfully constructed lentiviral plasmid is used for subsequent experiments. By the above method, a recombinant lentiviral expression vector pLKO.1-TRC-shABHD2 of ABHD2-shRNA was constructed.

[0028] The above experiments on the construction of lentiviral expression vector pLKO.1-TRC-shABHD2 were commissioned by Saiye Biotech Co., Ltd.

[0029] Example 3 Construction of ovarian cancer cells with stable knockdown of ABHD2 gene

[0030] 1. Materials and Reagents

[0031] KGN cells were obtained from Shanghai Hongshun Biotechnology Co., Ltd. DMEM / F12 medium and penicillin-streptomycin solution P / S (100×) were purchased from Gibco. Fetal bovine serum (FBS) was purchased from Lanzhou Rongye Biological Co., Ltd. RNA extraction kit, RNA reverse transcription kit and qPCR kit were purchased from TAKARA Biological Co., Ltd. Transfection aid Polybrene was purchased from Saiye Biotechnology Co., Ltd.

[0032] Complete cell culture medium: DMEM / F12 medium + 10% FBS + 1% P / S.

[0033] 2. Experimental steps

[0034] (1) Cell culture and transfection

[0035] KGN cells were plated in a 24-well cell culture dish. When the cells were in good condition and the density grew to 70%, the cells were transfected with the lentiviral expression vector pLKO.1-TRC-shABHD2 using Polybrene as the experimental group (5 μL lentiviral expression vector + 0.5 μL Polybrene + 500 μL complete cell culture medium) (shRNA group), and cultured in a 37°C incubator. At the same time, the cells were transfected with the empty lentiviral vector pLKO.1-TRC as the control group (Con group). The cells were collected after 72 hours and stored at -80°C.

[0036] (2) RNA extraction, reverse transcription, and qPCR

[0037] The specific experimental method of RNA extraction refers to TaKaRa MiniBEST Universal RNA Extraction Kit (Code NO.9767) produced by Takara Bio. After RNA extraction, its concentration was measured, and then RNA electrophoresis was used to detect the integrity of RNA. After the RNA quality passed, RNA reverse transcription and qPCR were performed. The specific experimental method refers to HiScript IIQ RT SuperMix for qPCR (Code NO.R222-01) and 2×ChamQ Universal SYBR qPCR Master Mix (Code NO.Q711-02) produced by Novozyme Biotechnology.

[0038] 3. Experimental results

[0039] like Figure 1 As shown, the knockdown rate of ABHD2 gene in the KGN cell shRNA group was about 3 times ( *** P < 0.001), indicating that the ABHD2 gene in KGN cells was successfully knocked down, and also indicating that the shRNA in Example 1 and the lentiviral expression vector pLKO.1-TRC-shABHD2 constructed in Example 2 can stably knock down the ABHD2 gene in KGN cells.

[0040] Example 4 Effect of ABHD2 gene knockdown on the proliferation activity of ovarian cancer cells

[0041] 1. Materials and Reagents

[0042] The CCK8 kit was purchased from Sewell.

[0043] 2. Experimental steps

[0044] (1) Cell culture and transfection

[0045] 100 μL of cell suspension was prepared in a 96-well plate. The culture plate was pre-cultured in an incubator. When the cells were in good condition and the density reached 70%, transfection was performed using the cell transfection method in Example 3. The control vector transfection was performed under the same conditions as in Example 3.

[0046] (2) Cell proliferation activity detection

[0047] When the transfection time was 72 h, 10 μL of CCK-8 solution was added to each well, and the culture plate was incubated in an incubator for 2 h. The absorbance at 450 nm was measured using an enzyme reader.

[0048] (3) Calculation of cell proliferation activity

[0049] Cell viability (%) = [A (shRNA group) - A (blank group)] / [A (Con group) - A (blank group)] × 100

[0050] A (shRNA group): absorbance of wells with cells, CCK-8 solution, and ABHD2-shRNA lentiviral expression vector;

[0051] A (blank group): absorbance of wells with culture medium and CCK-8 solution but no cells;

[0052] A (Con group): absorbance of wells with cells, CCK-8 solution, and control vector;

[0053] Cell viability: cell proliferation activity or cytotoxic activity.

[0054] 3. Experimental results

[0055] like Figure 2 As shown in the figure, compared with the control group (Con group), the proliferation activity of cells in the knockdown ABHD2 gene cell group (shRNA group) was significantly reduced ( ** P<0.01), indicating that silencing the expression of ABHD2 gene can inhibit the proliferation activity of ovarian cancer cells.

[0056] Example 5 Effect of ABHD2 gene knockdown on apoptosis of ovarian cancer cells

[0057] 1. Materials and Reagents

[0058] Hoechest 33342 reagent was purchased from Thermo Fisher Scientific.

[0059] 2. Experimental steps

[0060] (1) The cell plating culture and transfection steps were the same as those in Example 4.

[0061] (2) Dyeing

[0062] 72 hours after transfection, add Hochest33342 staining solution with a final concentration of 10 ng / mL. Add an appropriate amount of Hoechst33342 staining solution to fully cover the sample to be stained, and culture in a cell culture incubator for 20 to 30 minutes.

[0063] (3) Observation under microscope

[0064] Discard the staining solution, wash 2-3 times with PBS or culture medium, and then perform fluorescence detection.

[0065] 3. Experimental results

[0066] like Figure 3 As shown in A, when cells undergo apoptosis (shRNA group), observation under a fluorescence microscope shows that the nuclei of apoptotic cells are densely stained or densely stained in fragments.

[0067] like Figure 3 As shown in B, compared with the Con group, the apoptotic rate of cells in the shRNA group increased significantly ( * P<0.05), indicating that silencing the expression of ABHD2 gene can increase the apoptosis of ovarian cancer cells.

[0068] It can be seen from the results of the above examples that silencing the expression of the ABHD2 gene can inhibit the proliferation activity of ovarian cancer cells and increase the apoptosis of ovarian cancer cells, indicating that the shRNA targeted at silencing the expression of the ABHD2 gene provided by the present invention can be used as an effective tool for the treatment of ovarian cancer patients, providing a new idea for improving the cure rate of ovarian cancer.

[0069] The embodiments described above are only some embodiments of the present invention, rather than all embodiments. The detailed description of the embodiments of the present invention is not intended to limit the scope of the invention claimed for protection, but merely represents selected embodiments of the present invention. The scope of protection of the present invention shall be subject to the scope required by the claims. Based on the embodiments of the present invention, all other embodiments obtained by ordinary technicians in this field without creative work shall fall within the scope of protection of the present invention.

Claims

1. A shRNA targeting silencing ABHD2 gene expression, characterized in that: The nucleotide sequences of the shRNA are shown in SEQ ID NO.1 and SEQ ID NO.

2.

2. A lentiviral expression vector, characterized in that: Contains the shRNA targeted to silence ABHD2 gene expression as claimed in claim 1.

3. Use of the shRNA targeting silencing ABHD2 gene expression as claimed in claim 1, or the lentiviral expression vector as claimed in claim 2 in the preparation of a drug for treating ovarian cancer.

4. The use according to claim 3, characterized in that: The treatment includes inhibiting the proliferation of ovarian cancer cells and increasing the apoptosis of ovarian cancer cells.

5. The use according to claim 4, characterized in that: The ovarian cancer cells are KGN cells.

6. A pharmaceutical composition for treating ovarian cancer, characterized in that: It includes the shRNA targeting silencing ABHD2 gene expression as described in claim 1, or the lentiviral expression vector as described in claim 2.